Boston Scientific (BSX, Financial) has experienced a significant uptick in bearish options activity, with a total of 4,750 put contracts being traded—an increase of 1.6 times the expected daily volume. This heightened trading activity is primarily concentrated around two key options: the September 25th $75 puts and the April 25th weekly $100 calls, which together account for nearly 3,600 contracts.
The current Put/Call Ratio stands at 1.81, indicating a predominance of put activity over calls, suggestive of a bearish sentiment among traders. Meanwhile, at-the-money implied volatility (ATM IV) has risen by nearly 3 percentage points, reflecting greater market uncertainty as the company approaches its earnings release scheduled for April 23rd.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 30 analysts, the average target price for Boston Scientific Corp (BSX, Financial) is $116.34 with a high estimate of $130.00 and a low estimate of $84.11. The average target implies an upside of 23.72% from the current price of $94.03. More detailed estimate data can be found on the Boston Scientific Corp (BSX) Forecast page.
Based on the consensus recommendation from 34 brokerage firms, Boston Scientific Corp's (BSX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Boston Scientific Corp (BSX, Financial) in one year is $76.94, suggesting a downside of 18.18% from the current price of $94.03. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Boston Scientific Corp (BSX) Summary page.
